Targeted conditioning with anti-CD45 iodine (I-131) apamistamab [Iomab-B] leads to high rates of allogeneic transplantation and successful engraftment in older patients with active, relapsed or refractory (rel/ref) AML after failure of chemotherapy and targeted agents: Preliminary midpoint results from the prospective, randomized phase 3 SIERRA trial Meeting Abstract
| Authors: | Gyurkocza, B.; Nath, R.; Stiff, P. J.; Agura, E.; Litzow, M. R.; Tomlinson, B.; Choe, H.; Abhyankar, S.; Seropian, S. E.; Chen, G. L.; Hari, P.; Al-Kadhimi, Z.; Foran, J.; Orozco, J. J.; van Besien, K.; Sabloff, M.; Kebriaei, P.; Abboud, C.; Levy, M. Y.; Lazarus, H. M.; Giralt, S. A.; Berger, M. S.; Reddy, V.; Pagel, J. M. |
| Abstract Title: | Targeted conditioning with anti-CD45 iodine (I-131) apamistamab [Iomab-B] leads to high rates of allogeneic transplantation and successful engraftment in older patients with active, relapsed or refractory (rel/ref) AML after failure of chemotherapy and targeted agents: Preliminary midpoint results from the prospective, randomized phase 3 SIERRA trial |
| Meeting Title: | Transplantation and Cellular Therapy Meetings of ASBMT and CIBMTR |
| Journal Title: | Biology of Blood and Marrow Transplantation |
| Volume: | 26 |
| Issue: | 3 Suppl. |
| Meeting Dates: | 2020 Feb 19-23 |
| Meeting Location: | Orlando, FL |
| ISSN: | 1083-8791 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2020-03-01 |
| Start Page: | S32 |
| End Page: | S33 |
| Language: | English |
| ACCESSION: | WOS:000516887900040 |
| PROVIDER: | wos |
| DOI: | 10.1016/j.bbmt.2019.12.575 |
| Notes: | Meeting Abstract: 39 -- Source: Wos |
